Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2022 Earnings Conference Call March 23, 2023 8:00 AM ET

Company Participants

Daniel Kontoh-Boateng - Investor Relations

Lisa Ricciardi - President and Chief Executive Officer

Andrew Einhorn - Interim Chief Financial Officer

Tony Caggiano - Chief Medical Officer and Head of R&D

Conference Call Participants

Charles Duncan - Cantor Fitzgerald

Jay Olson - Oppenheimer

Mayank Mamtani - B. Riley Securities

Operator

Good morning, ladies and gentlemen, and welcome to Cognition Therapeutics Incorporated Fourth Quarter and Fiscal Year 2022 Earnings Conference Call. My name is Julianne and I will be your conference operator today. This call is being recorded.

I would like to turn the presentation over now to your host for today's call, Daniel Kontoh-Boateng, Investor Relations for Cognition Therapeutics. Please go ahead, Mr. Kontoh-Boateng.

Daniel Kontoh-Boateng

Thank you, Julianne. Good morning and thank you for participating in Cognition Therapeutics conference call today. With me today are Lisa Ricciardi, President and Chief Executive Officer of Cognition; and Andrew Einhorn, Interim Chief Financial Officer of Cognition.

A press release detailing Cognition Therapeutics 2022 results is available on the Investors section of our website at cogrx.com. We encourage everyone to read this morning's press release as well as Cognition's Annual Report on Form 10-K, which is now filed with the SEC and available on our website. In addition, this conference call is being webcast through the company's website and will be archived for 30 days.

Please note that certain information discussed on the call today is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call, management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in Cognition's press releases and SEC filings, including its annual report on Form 10-K and previous filings. This conference call contains time sensitive information that is accurate only as of the date of this live broadcast. Cognition undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call.

With that, I would now like to hand the call over to Lisa Ricciardi. Lisa?

Lisa Ricciardi

Thank you, Daniel. Good morning, everyone and welcome to Cognition Therapeutics' earnings conference call covering 2022's results. On today's call, our Interim Chief Financial Officer, Andy Einhorn and I will share prepared remarks on the company's progress and financial performance in 2022, after which we'll be joined by Dr. Tony Caggiano, our Chief Medical Officer and Head of R&D in order to take your questions.